Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer
Abstract
B7 homolog 3 (B7‐H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD‐L1. Immunotherapies (antibodies, antibody‐drug conjugates, and chimeric antigen receptor T cells) targeting B7‐H3 are currently in clinical trials; therefore, elucidating the molecular and immune microenvironment correlates of B7‐H3 expression may help to guide trial design and interpretation. The authors tested the interconnected hypotheses that B7‐H3 expression is associated with genetic racial ancestry, immune cell composition, and androgen receptor signaling in PCa.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 25, 2022
- Source ID
- 10.1002/cncr.34190
Entities
People
- Adam B. Weiner
- Adrianna A. Mendes
- Angelo M De Marzo
- Ashley E. Ross
- Corinne Joshu
- Edward M. Schaeffer
- Emirhan Tekoglu
- Emmanuel S. Antonarakis
- Eugene Shenderov
- Harsimar B. Kaur
- Janielle P Maynard
- Jessica Hicks
- Jianfeng Xu
- Jiayun Lu
- Karen S Sfanos
- Mary‐ellen Taplin
- Nathan A. Lack
- Siqun L. Zheng
- Steven P Balk
- Tamara L Lotan
Organizations
- Dana–Farber Cancer Institute
- Harvard Medical School
- Johns Hopkins University
- Koç University
- National Cancer Institute
- NorthShore University HealthSystem
- Northwestern University
- Prostate Cancer Foundation
- Sidney Kimmel Comprehensive Cancer Center
- United States Department of Defense
- University of British Columbia